1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy

Blood glucose elevates at initial high-dose steroid (HDS) administration and is prolonged by persistent amplification of glucagon-induced glycogenesis. Insulin (INS) administration at initial dose of HDS will avoid this. However, INS administration criteria regarding BS elevation are not defined. HD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1)
Hauptverfasser: KANEKO, SHIZUKA, MOTOHASHI, KAZUYA, MINAMI, TOMOKO, UEBA, YOKO, OSUGI, TOMOAKI, TOKUMOTO, SHINSUKE
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 71
creator KANEKO, SHIZUKA
MOTOHASHI, KAZUYA
MINAMI, TOMOKO
UEBA, YOKO
OSUGI, TOMOAKI
TOKUMOTO, SHINSUKE
description Blood glucose elevates at initial high-dose steroid (HDS) administration and is prolonged by persistent amplification of glucagon-induced glycogenesis. Insulin (INS) administration at initial dose of HDS will avoid this. However, INS administration criteria regarding BS elevation are not defined. HDS were given based on COVID-treatment guidelines. HDS administration circumstances in clinical settings may clarify these criteria. The necessity of INS therapy at initial HDS administration is studied. COVID-inpatients receiving HDS, regarding a COVID-period in Japan comprising 5 waves, were sub-grouped into those requiring INS therapy and those not, and analyzed with respect to age, BMI, fasting blood glucose (FBS) , A1c, C-peptide (CPR) index, CPR/glucagon (GCG) . INS was administered, target BS level 200 mg/dL or less at 14:00, depending on BS level after HDS administration. From 396 patients, 257 received HDS as follows, 1of the 154 patients in Wave 1-3 (69.5 ± 16.7 years, BMI 23.9 ± 4.8%, A1c 6.3 ± 1.1%) , 79 of the 83 patients in Wave 4 (64.5 ± 14.6 years, BMI 24.9 ± 4.78, A1c 6.6 ± 1.1%) , and 73 of the 117 patients in Wave 5 (54.4 ± 15.2 years, BMI 25.2 ± 5.1, A1c 6.2 ± 0.8%) . Of the 257 patients above, 145 were treated with INS. In all Waves, only FBS and A1c differed significantly between INS-treated and non-INS-treated patients. ROC analysis in Wave 1-3, Wave 4 and Wave 5 showed cut-off values of A1c (sensitivity/specificity) and FBS (sensitivity/specificity) measuring 6.1% (0.85/0.62) and 121.5 mg/dL (1.00/ 0.62) , 6.5% (0.44/0.83) and133.5 mg/dL (0.40/0.93) , and 6.4% (0.49/1.0) and 112.5 mg/dL (0.81/0.85) , respectively. In patients with FBS levels of 112.5 mg/dL or higher or A1c levels of 6.3% or higher, the use of INS from the initial HDS administration reduced prolongation of hyperglycemia. Variables BMI, CPR, and GCG secretion cannot determine the need for INS therapy. It is important to use FBS and A1c levels, according to conventional practice, to ascertain if INS administration is necessary.
doi_str_mv 10.2337/db22-1386-P
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2685591469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2685591469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c649-9691be5b2133c1da9cfef661cd9eca0c2f3a244d17af23525de4c5821df91ab73</originalsourceid><addsrcrecordid>eNotkE1LAzEQhoMoWKsn_0DAo6xmkt1s460sfhQKFroHbyGbD5rSbmqSHvrv3XZlDu9hnncGHoQegbxQxupX01FaAJvxYnWFJiCYKBitf67RhBAYNrWob9FdSltCCB9mguRIv-Em9M7Hvco-9Dg4nDcWN9FnG73CLkS86NNx53s8N3vf-5TjiKp8QddZxXzurYdG8Aa3GxvV4XSPbpzaJfvwn1PUfry3zVex_P5cNPNloXkpCsEFdLbqKDCmwSihnXWcgzbCakU0dUzRsjRQK0dZRStjS13NKBgnQHU1m6Kn8ewhht-jTVluwzH2w0dJ-ayqBJRcDNTzSOkYUorWyUP0exVPEog8C5RngRclcsX-AMMkYxE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685591469</pqid></control><display><type>article</type><title>1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>KANEKO, SHIZUKA ; MOTOHASHI, KAZUYA ; MINAMI, TOMOKO ; UEBA, YOKO ; OSUGI, TOMOAKI ; TOKUMOTO, SHINSUKE</creator><creatorcontrib>KANEKO, SHIZUKA ; MOTOHASHI, KAZUYA ; MINAMI, TOMOKO ; UEBA, YOKO ; OSUGI, TOMOAKI ; TOKUMOTO, SHINSUKE</creatorcontrib><description>Blood glucose elevates at initial high-dose steroid (HDS) administration and is prolonged by persistent amplification of glucagon-induced glycogenesis. Insulin (INS) administration at initial dose of HDS will avoid this. However, INS administration criteria regarding BS elevation are not defined. HDS were given based on COVID-treatment guidelines. HDS administration circumstances in clinical settings may clarify these criteria. The necessity of INS therapy at initial HDS administration is studied. COVID-inpatients receiving HDS, regarding a COVID-period in Japan comprising 5 waves, were sub-grouped into those requiring INS therapy and those not, and analyzed with respect to age, BMI, fasting blood glucose (FBS) , A1c, C-peptide (CPR) index, CPR/glucagon (GCG) . INS was administered, target BS level 200 mg/dL or less at 14:00, depending on BS level after HDS administration. From 396 patients, 257 received HDS as follows, 1of the 154 patients in Wave 1-3 (69.5 ± 16.7 years, BMI 23.9 ± 4.8%, A1c 6.3 ± 1.1%) , 79 of the 83 patients in Wave 4 (64.5 ± 14.6 years, BMI 24.9 ± 4.78, A1c 6.6 ± 1.1%) , and 73 of the 117 patients in Wave 5 (54.4 ± 15.2 years, BMI 25.2 ± 5.1, A1c 6.2 ± 0.8%) . Of the 257 patients above, 145 were treated with INS. In all Waves, only FBS and A1c differed significantly between INS-treated and non-INS-treated patients. ROC analysis in Wave 1-3, Wave 4 and Wave 5 showed cut-off values of A1c (sensitivity/specificity) and FBS (sensitivity/specificity) measuring 6.1% (0.85/0.62) and 121.5 mg/dL (1.00/ 0.62) , 6.5% (0.44/0.83) and133.5 mg/dL (0.40/0.93) , and 6.4% (0.49/1.0) and 112.5 mg/dL (0.81/0.85) , respectively. In patients with FBS levels of 112.5 mg/dL or higher or A1c levels of 6.3% or higher, the use of INS from the initial HDS administration reduced prolongation of hyperglycemia. Variables BMI, CPR, and GCG secretion cannot determine the need for INS therapy. It is important to use FBS and A1c levels, according to conventional practice, to ascertain if INS administration is necessary.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db22-1386-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Blood glucose ; Diabetes ; Glucagon ; Hyperglycemia ; Insulin ; Patients ; Steroids</subject><ispartof>Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>KANEKO, SHIZUKA</creatorcontrib><creatorcontrib>MOTOHASHI, KAZUYA</creatorcontrib><creatorcontrib>MINAMI, TOMOKO</creatorcontrib><creatorcontrib>UEBA, YOKO</creatorcontrib><creatorcontrib>OSUGI, TOMOAKI</creatorcontrib><creatorcontrib>TOKUMOTO, SHINSUKE</creatorcontrib><title>1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy</title><title>Diabetes (New York, N.Y.)</title><description>Blood glucose elevates at initial high-dose steroid (HDS) administration and is prolonged by persistent amplification of glucagon-induced glycogenesis. Insulin (INS) administration at initial dose of HDS will avoid this. However, INS administration criteria regarding BS elevation are not defined. HDS were given based on COVID-treatment guidelines. HDS administration circumstances in clinical settings may clarify these criteria. The necessity of INS therapy at initial HDS administration is studied. COVID-inpatients receiving HDS, regarding a COVID-period in Japan comprising 5 waves, were sub-grouped into those requiring INS therapy and those not, and analyzed with respect to age, BMI, fasting blood glucose (FBS) , A1c, C-peptide (CPR) index, CPR/glucagon (GCG) . INS was administered, target BS level 200 mg/dL or less at 14:00, depending on BS level after HDS administration. From 396 patients, 257 received HDS as follows, 1of the 154 patients in Wave 1-3 (69.5 ± 16.7 years, BMI 23.9 ± 4.8%, A1c 6.3 ± 1.1%) , 79 of the 83 patients in Wave 4 (64.5 ± 14.6 years, BMI 24.9 ± 4.78, A1c 6.6 ± 1.1%) , and 73 of the 117 patients in Wave 5 (54.4 ± 15.2 years, BMI 25.2 ± 5.1, A1c 6.2 ± 0.8%) . Of the 257 patients above, 145 were treated with INS. In all Waves, only FBS and A1c differed significantly between INS-treated and non-INS-treated patients. ROC analysis in Wave 1-3, Wave 4 and Wave 5 showed cut-off values of A1c (sensitivity/specificity) and FBS (sensitivity/specificity) measuring 6.1% (0.85/0.62) and 121.5 mg/dL (1.00/ 0.62) , 6.5% (0.44/0.83) and133.5 mg/dL (0.40/0.93) , and 6.4% (0.49/1.0) and 112.5 mg/dL (0.81/0.85) , respectively. In patients with FBS levels of 112.5 mg/dL or higher or A1c levels of 6.3% or higher, the use of INS from the initial HDS administration reduced prolongation of hyperglycemia. Variables BMI, CPR, and GCG secretion cannot determine the need for INS therapy. It is important to use FBS and A1c levels, according to conventional practice, to ascertain if INS administration is necessary.</description><subject>Blood glucose</subject><subject>Diabetes</subject><subject>Glucagon</subject><subject>Hyperglycemia</subject><subject>Insulin</subject><subject>Patients</subject><subject>Steroids</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNotkE1LAzEQhoMoWKsn_0DAo6xmkt1s460sfhQKFroHbyGbD5rSbmqSHvrv3XZlDu9hnncGHoQegbxQxupX01FaAJvxYnWFJiCYKBitf67RhBAYNrWob9FdSltCCB9mguRIv-Em9M7Hvco-9Dg4nDcWN9FnG73CLkS86NNx53s8N3vf-5TjiKp8QddZxXzurYdG8Aa3GxvV4XSPbpzaJfvwn1PUfry3zVex_P5cNPNloXkpCsEFdLbqKDCmwSihnXWcgzbCakU0dUzRsjRQK0dZRStjS13NKBgnQHU1m6Kn8ewhht-jTVluwzH2w0dJ-ayqBJRcDNTzSOkYUorWyUP0exVPEog8C5RngRclcsX-AMMkYxE</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>KANEKO, SHIZUKA</creator><creator>MOTOHASHI, KAZUYA</creator><creator>MINAMI, TOMOKO</creator><creator>UEBA, YOKO</creator><creator>OSUGI, TOMOAKI</creator><creator>TOKUMOTO, SHINSUKE</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20220601</creationdate><title>1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy</title><author>KANEKO, SHIZUKA ; MOTOHASHI, KAZUYA ; MINAMI, TOMOKO ; UEBA, YOKO ; OSUGI, TOMOAKI ; TOKUMOTO, SHINSUKE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c649-9691be5b2133c1da9cfef661cd9eca0c2f3a244d17af23525de4c5821df91ab73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Blood glucose</topic><topic>Diabetes</topic><topic>Glucagon</topic><topic>Hyperglycemia</topic><topic>Insulin</topic><topic>Patients</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KANEKO, SHIZUKA</creatorcontrib><creatorcontrib>MOTOHASHI, KAZUYA</creatorcontrib><creatorcontrib>MINAMI, TOMOKO</creatorcontrib><creatorcontrib>UEBA, YOKO</creatorcontrib><creatorcontrib>OSUGI, TOMOAKI</creatorcontrib><creatorcontrib>TOKUMOTO, SHINSUKE</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KANEKO, SHIZUKA</au><au>MOTOHASHI, KAZUYA</au><au>MINAMI, TOMOKO</au><au>UEBA, YOKO</au><au>OSUGI, TOMOAKI</au><au>TOKUMOTO, SHINSUKE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2022-06-01</date><risdate>2022</risdate><volume>71</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Blood glucose elevates at initial high-dose steroid (HDS) administration and is prolonged by persistent amplification of glucagon-induced glycogenesis. Insulin (INS) administration at initial dose of HDS will avoid this. However, INS administration criteria regarding BS elevation are not defined. HDS were given based on COVID-treatment guidelines. HDS administration circumstances in clinical settings may clarify these criteria. The necessity of INS therapy at initial HDS administration is studied. COVID-inpatients receiving HDS, regarding a COVID-period in Japan comprising 5 waves, were sub-grouped into those requiring INS therapy and those not, and analyzed with respect to age, BMI, fasting blood glucose (FBS) , A1c, C-peptide (CPR) index, CPR/glucagon (GCG) . INS was administered, target BS level 200 mg/dL or less at 14:00, depending on BS level after HDS administration. From 396 patients, 257 received HDS as follows, 1of the 154 patients in Wave 1-3 (69.5 ± 16.7 years, BMI 23.9 ± 4.8%, A1c 6.3 ± 1.1%) , 79 of the 83 patients in Wave 4 (64.5 ± 14.6 years, BMI 24.9 ± 4.78, A1c 6.6 ± 1.1%) , and 73 of the 117 patients in Wave 5 (54.4 ± 15.2 years, BMI 25.2 ± 5.1, A1c 6.2 ± 0.8%) . Of the 257 patients above, 145 were treated with INS. In all Waves, only FBS and A1c differed significantly between INS-treated and non-INS-treated patients. ROC analysis in Wave 1-3, Wave 4 and Wave 5 showed cut-off values of A1c (sensitivity/specificity) and FBS (sensitivity/specificity) measuring 6.1% (0.85/0.62) and 121.5 mg/dL (1.00/ 0.62) , 6.5% (0.44/0.83) and133.5 mg/dL (0.40/0.93) , and 6.4% (0.49/1.0) and 112.5 mg/dL (0.81/0.85) , respectively. In patients with FBS levels of 112.5 mg/dL or higher or A1c levels of 6.3% or higher, the use of INS from the initial HDS administration reduced prolongation of hyperglycemia. Variables BMI, CPR, and GCG secretion cannot determine the need for INS therapy. It is important to use FBS and A1c levels, according to conventional practice, to ascertain if INS administration is necessary.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db22-1386-P</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_proquest_journals_2685591469
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Blood glucose
Diabetes
Glucagon
Hyperglycemia
Insulin
Patients
Steroids
title 1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A15%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1386-P:%20Confirmation%20of%20the%20Criteria%20for%20Insulin%20Administration%20at%20the%20Start%20of%20Steroid%20Therapy&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=KANEKO,%20SHIZUKA&rft.date=2022-06-01&rft.volume=71&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db22-1386-P&rft_dat=%3Cproquest_cross%3E2685591469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685591469&rft_id=info:pmid/&rfr_iscdi=true